Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Brehanna Edwards, PGY-2 Health-System Pharmacy Administration and Leadership Resident at Ascension, shared on LinkedIn:
”Publication Alert
I’m excited to share that our latest work, “Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE,” has just been published in the Journal of Thrombosis and Thrombolysis.
This multicenter study across 29 hospitals examined whether patients with acute VTE who received prior therapeutic parenteral anticoagulation truly require a full lead-in period of apixaban or rivaroxaban.
Our findings suggest that a reduced lead-in strategy is not associated with increased risk of VTE recurrence or major bleeding, offering important real-world evidence to inform clinical decision-making.
Grateful for the collaborative effort behind this project and excited for the ongoing conversation about optimizing anticoagulation strategies in acute VTE care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 26, 2026, 16:58Paul Whiteley: Iron Deficiency and Behavioral Problems in Children With Autism
-
Sep 26, 2026, 16:41Matthew Smeds: Management of Thoracic Endograft Thrombosis and Mesenteric Embolization
-
Sep 26, 2026, 16:04Isabelle Feldhaus: What the New ASH Iron Deficiency Guidance Means for Care
-
Sep 26, 2026, 15:55Francesca Palandri: The R-NAT Score Developed in Ruxolitinib-Treated MF Patients
-
Sep 26, 2026, 15:49Alex Ehsan: Antiphospholipid Syndrome – A Practical Guide
-
Sep 26, 2026, 15:42Michael Tadao Inouye: The Next Frontier in Genomic Population Health
-
Sep 26, 2026, 15:32Katariina Öörni: Familial Hypercholesterolaemia in Children Why Early Diagnosis Matters
-
Sep 26, 2026, 15:30P-Selectin as a Therapeutic Target in Thrombosis
-
Sep 26, 2026, 15:27Berkan Kurt: The Role of Biomarkers in Cardiovascular Prevention